DJIA 16,276.49 218.14 1.36%
NASDAQ 4,710.53 74.43 1.61%
S&P 500 1,938.62 24.77 1.29%
market minute promo

Merck & Co., Inc. (NYSE: MRK)



company name or ticker
Company Photos
(Click to zoom)

A Review Of Gilead's Pipeline (Part 2): Focus On Zydelig And Lymphoma/CLL Candidates

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN and the TECOS Cardiovascular Safety Trial

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN and the TECOS Cardiovascular Safety Trial of JANUVIA Will Be Presented at the European Society of Cardiology Congress

Esperion Updates on its Cholesterol Management Candidate

Merck's Keytruda under FDA Review for First-Line Melanoma

Almost A Quarter Of Bristol-Myers Squibb’s Valuation Is Dependent On Yervoy’s & Nivolumab’s Growth

Merck's Pipeline Speaks Of Long-Term Health

Are You Paying Too Much For Merck?

Using Attribution Analysis To Gain Perspective On Actively Managed Funds

Something Big Is Happening With Big Pharma

You probably missed it, but a big shift is underway in Big Pharma stocks.

Health Care Sector Update for 08/18/2015: TROV, LJPC, MRK

See More Articles...